Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity
Korean Journal of Ophthalmology
;
: 466-472, 2014.
Article
in English
| WPRIM
| ID: wpr-30316
ABSTRACT
PURPOSE:
To investigate 12-month treatment outcomes of anti-vascular endothelial growth factor therapy in eyes with typical exudative age-related macular degeneration with good baseline visual acuity.METHODS:
This retrospective observational case series included 18 eyes (18 patients) with typical exudative age-related macular degeneration with a baseline best-corrected visual acuity of 20 / 25 or better. Patients were treated with anti-vascular endothelial growth factor monotherapy during the 12-month follow-up period. Baseline visual acuity and central foveal thickness were compared to the values at 12 months.RESULTS:
Patients received an average of 4.4 +/- 1.3 intravitreal anti-vascular endothelial growth factor injections. The mean logarithm of minimum angle of resolution visual acuity was 0.08 +/- 0.04, 0.08 +/- 0.07, 0.12 +/- 0.09, and 0.16 +/- 0.11 at baseline, three months, six months, and 12 months, respectively. Visual acuity at 12 months was significantly worse than the baseline value at diagnosis (p = 0.017), and the mean central foveal thickness at the defined time points was 270.2 +/- 55.6, 204.4 +/- 25.4, 230.1 +/- 56.3, and 216.8 +/- 48.7 microm, respectively. The central foveal thickness at 12 months was significantly less than the baseline value at diagnosis (p = 0.042).CONCLUSIONS:
Deterioration in visual acuity was noted in eyes with typical exudative age-related macular degeneration with good baseline visual acuity, suggesting the need for close patient monitoring and prompt treatment even in patients with good baseline visual acuity.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Fluorescein Angiography
/
Visual Acuity
/
Retrospective Studies
/
Choroidal Neovascularization
/
Angiogenesis Inhibitors
/
Vascular Endothelial Growth Factor A
/
Tomography, Optical Coherence
/
Wet Macular Degeneration
/
Intravitreal Injections
/
Bevacizumab
Type of study:
Observational study
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Korean Journal of Ophthalmology
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS